Menu Search
Equities

VivoSim Labs Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0R02:LSE

VivoSim Labs Inc

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta1.2338
Data delayed at least 20 minutes, as of Mar 20 2025.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The Company offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. It uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The Company's 3D human tissue platform is multifaceted. The Company has expertise in 3D organoids, such as spheroids, and has made advances in proprietary cell culture techniques including ratios, components and conditions.

  • Revenue in USD (TTM)140.00k
  • Net income in USD-1.98m
  • Incorporated2012
  • Employees5.00
  • Location
    VivoSim Labs Inc11555 Sorrento Valley Road, Suite 100SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 224-1000
  • Fax+1 (302) 636-5454
  • Websitehttps://organovo.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.